Author stories Proactiveinvestors Author stories RSS feed en Thu, 19 Apr 2018 22:26:45 +0100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) Uranium Energy building exciting portfolio as demand fundamentals improve Uranium Energy chief executive Amir Adnani discusses the group’s fully licensed and developed Hobson processing plant in Texas, which is an important strategic element of the group’s growth plans.
Processing and infrastructure is a premium component for uranium business, as availability has typically been limited, he explains.
“So we’re definitely in a strong position with Hobson as, really, the heart of what we call our hub and spoke strategy,” he said.
Adnani talks about the group’s low cost and environmentally friendly approach to uranium mining, via in-situ recovery methods.

Thu, 29 Sep 2016 12:15:00 +0100
Salamanca will have' incredibly good' margins says Berkeley's Schumann Things are falling into place for Berkeley Energia’s (LON:BKY) Salamanca uranium project in Spain with the latest news the appointment of heavyweight engineering firm Amec Foster Wheeler to design the mine.

It follows quickly on from last week’s offtake agreement that will guarantee a price of US$41 per pound of uranium produced.

As operating costs are estimated at US$15 per lb, it should mean an ‘incredibly good margin’ says Hugo Schumann, corporate manager.

Next steps will be finalising the US$100mmln funding to build the mine alongside more offtake and marketing deals where the publication of the definitive feasibility study has generated a stack of interest, he says.   

Wed, 28 Sep 2016 11:35:00 +0100
Faron Pharmaceuticals Oy’s options widen after fund-raising Demand for shares in Faron Pharmaceuticals Oy’s (LON:FARN) was strong when the company tapped the City last week for £8mln to fund the development of its two lead drugs.
Faron’s chief executive (CEO), Dr Markku Jalkanen, tells Proactive Investors the fund-raising has brought “quite a number of UK institutional investors” on to the shareholder register.
Some of the new funding will pay for a phase I/II trial in the US of Traumakine, its lead product, in patients with a heart condition called rupture of abdominal aorta aneurysm.
“It’s really important for us to get activities on the US side, specifically for our lead product. We want to conduct a safety trial there, which was the advice given by the [US] Food and Drug Administration, and this will take up maybe half of the proceeds raised at this time,” Dr Jalkanen said.
Some has been kept aside for the pre-clinical and early clinical development of Clevegen, an antibody that could help the body’s own immune system tackle cancer.
“Clevegen is becoming more and more interesting,” the CEO said.
Early stage biotechs are no strangers to fund-raising and there may be another share issue in the offing next year but it is not the only option on the table, Dr Jalkanen said, opening up the possibility of partnership or licensing activities.

Wed, 28 Sep 2016 11:01:00 +0100
Union Jack Oil "over the moon" with latest Wressle stake acquisition David Bramhill, chairman at Union Jack Oil (LON:UJO) talks to Proactive Investors after the company increased its stake in the Wressle field.

Given the project's potential, Bramhill feels the company paid "a very nice price for this".

"The cashflow we'll be getting from this will make a big difference to our balance sheet.

"We are over the moon with this acquisition, and make no secret we'd like more" he says.

Wed, 28 Sep 2016 10:37:00 +0100
Focus remains US, says expanding Allergy Therapeutics Allergy Therapeutics (LON:AGY) chief executive Manuel Llobet said: “It’s been quite a good year, we have progressed on all of our strategic goals, namely progressing on our businesses in Europe.”

Allergy Therapeutics said the global allergy treatment market had seen some “turmoil” affecting the competitive market environment in Europe and the US, but the group said it would likely see mid to long-term benefits in terms of its US market share.

“We are building a nice, thriving, sound company in the European market,” says Llobet, but focus remains the US.

“The biggest opportunity we want to tap is the US, that’s our focus,” he says.

The group plans to add two or three new markets a year to expand its portfolio franchise.

Wed, 28 Sep 2016 10:02:00 +0100
Sareum Holdings' chief says licensing deal with ProNai validates strategy Sareum Holdings Plc's (LON:SAR) chief executive Dr Tim Mitchell told Proactive that the licensing of its cancer drug  Chk1 Inhibitor CCT245737 to New York listed  ProNAi Therapeutics validate the group strategy and provided it with useful cash.
Under agreements with Cancer Research Technology (CRT) and the CRT Pioneer Fund, the drug discovery group will receive US$1.9mln as an up-front payment and potential future milestone payments of up to US$88.4mln, some of which will be paid within the next year.
From future royalties of sales of the drug, the group could make 2/ 2.5% on royalties on a drug, which could sell hundreds of millions of dollars.
"Our model is to take our drug research through the discovery process and early clinical trials and then look for licensing deals and that's exactly what  we've done."
Dr Mitchell said that strategy would not change, with the other programmes in its pipeline.
Earlier the firm had said: “ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the United States and with broader clinical studies. We look forward to reporting on their progress."

Tue, 27 Sep 2016 16:47:00 +0100
Capital Network's Catalano spells out potential of Harvest Mineral's Brazil project Harvest Minerals Limited's  (LON:HMI) Arapua fertiliser project in Minas Gerais, Brazil is a "fantastic one", according to Capital Network analyst Sam Catalano.
Speaking to Proactive's stocktube team, he said the project should be coming into production later this year.
Among its credentials, it is a very low capex start up, costing only up to $400,000 to get going, he says, since it's a case  of simply digging the potash up from the ground and putting it on a truck.
It will be able sell the fertiliser at around $50 per tonne, while operating costs are less than $10 a tonne.
At a profit of around $40 a tonne, he reckons the project could yield free cash flow in double digits within the next couple of years.
The analyst added that Brazil was a faster growing market for fertiliser than the rest of the world.

Tue, 27 Sep 2016 16:04:00 +0100
NetScientific PLC focused on “execution, execution and execution” Biomedical and healthcare incubator NetScientific PLC (LON:NSCI) had a busy first half to the year, focusing on “execution, execution, execution”, according to chief executive officer François Martelet.
Backed by its world class scientific advisory boards, the investment company’s emphasis has been on accelerating its core portfolio companies - Wanda, Vortex Biosciences, Glycotest and ProAxsis - towards the commercialisation stage. That will set them up nicely for time when external funding will be needed to capitalise on the market opportunities.
ProAxsis is already on the cusp of fund-raising, and will seek external backers before the end of the year while Wanda, which now has an experienced CEO on board, also plans to seek external funding to capitalise on the significant opportunities in the digital healthcare space.
Martelet said the second half is set to be just as busy for those companies, and as they emerge from the development stage Martelet said the company would be looking to replenish the pipeline.
“We are certainly looking at organic growth … but we are looking at game changing technologies in the UK, in Europe and in the US as well to achieve that goal.”

Tue, 27 Sep 2016 15:35:00 +0100
Silence Therapeutics plc defending its IP in the exciting gene silencing space Speaking to Proactive's stocktube team, chief executive of Silence Therapeutics PLC (LON:SLN) Ali Mortazavi highlighted the progress the biotech firm has made and reiterated that, at its core, it was a drug development firm.
"We are trying to make novel drugs," he said, adding that the focus of its development products were on the human liver.
All biotech companies are made up of important intellectual property (IP) and its products, he added.
Relating to its IP, the firm is involved in some complex legal maneuverings, and it looks out for any company which starts to develop a drug in the RNA space, in which as yet no drug has approval. That's because it could potentially infringe on Silence’s IP.
An early example of a licensing deal came from Quark Pharmaceuticals, which licensed Silence’s technology ten years ago and is a partner with the group and has development drugs now in phase II and phase III clinical trials.
The two are currently however in arbitration over a $3mln milestone payment, which Silence believes it is owed.
Mortazavi pointed out however that this dispute has nothing to do with payments that will be due when and if the drugs are approved.
Earlier, in its interim results update, the firm revealed it will seek a partner for its flagship pancreatic cancer drug Atu027 following the release earlier this year of results from its phase II clinical trial.

Tue, 27 Sep 2016 14:46:00 +0100
Europa Oil & Gas boss says Wressle deal is "win-win" Speaking with Proactive Investors’ Stocktube about a deal to sell a portion of its stake in the Wressle field for £600,000 in cash, Europa Oil & Gas (LON:EOG) chief executive Hugh Mackay says “everything is for sale at the right price”.
Mackay emphasises that Europa is an explorer, and he felt that monetising a small percentage of Wressle was a win-win not just for the company but partner Union Jack Oil as well.
He added that the £5.4mln valuation for the remainder of Europa’s stake in Wressle represents an important benchmark.
Mackay also discusses Wressle’s continuing development and the plans for the Holmwood well, where it Europa plans to spend the cash proceeds.
Holmwood is one of the best conventional oil prospects remaining onshore UK, Mackay added.

Tue, 27 Sep 2016 10:31:00 +0100
VSA Capital Market Movers - Zambeef Products, RCL Foods VSA Agri Thought for the Month

This month saw a UK-listed stock operating in the African agriculture sector with a market capitalisation of just US$26m attract a US$65m funding package from CDC Group, the UK’s development finance institution.

As we said at the time this is an extremely significant (and unexpected) deal for Zambeef Products (LON:ZAM), which had otherwise been poised to deliver significant dilution to its investors (c50%) to satisfy an outstanding put option on its poultry joint ventures with RCL Foods (JSE:RCL).

In This Issue
In this issue we have taken a look at the African agriculture sector more widely and asked whether this deal signals a revival of investor interest in the sector as a whole or just a specific bright point in what has been a pretty disappointing sector for public equity investors over the last few years.

The note also contains our regular features - stocks that we have been recently discussing with investors, changes to global crop forecasts, performance of our primary crop production index and commentary on global commodity price movements.
• African Agriculture Stocks: Renewed Hope?
• Selected Company News from the Past Month
• Stocks on Our Radar
• USDA Global Crop Forecasts, 2016/17
• The VSA Primary Crop Production Index
• Commodity Pricing and Comments

Wed, 31 Aug 2016 14:46:00 +0100